Bristol-Myers Squibb (BMY) Provides Update on Pending Transaction with Celgene (CELG), Says Remains on Track to Close in Q3

February 20, 2019 9:02 AM
Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on its proposed acquisition of Celgene Corporation (NASDAQ: CELG). Bristol-Myers Squibb ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News Mergers and Acquisitions

Next Articles